MLA
MRNA icon

MB, Levis & Associates’s Moderna MRNA Stock Holding History

MB, Levis & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-127
Closed -$3.28K – 254
2025
Q3 		$3.28K Hold
127
– – ﹤0.01% 198
2025
Q2 		$3.5K Hold
127
– – ﹤0.01% 231
2025
Q1 		$3.6K Hold
127
– – ﹤0.01% 231
2024
Q4 		$5.28K Hold
127
– – ﹤0.01% 216
2024
Q3 		$8.49K Hold
127
– – ﹤0.01% 200
2024
Q2 		$15.1K Hold
127
– – 0.01% 169
2024
Q1 		$13.5K Hold
127
– – 0.01% 175
2023
Q4 		$12.6K Hold
127
– – 0.01% 178
2023
Q3 		$13.1K Hold
127
– – 0.01% 177
2023
Q2 		$15.4K Hold
127
– – 0.01% 171
2023
Q1 		$19.5K Hold
127
– – 0.01% 158
2022
Q4 		$22.8K Buy
+127
New +$20.8K 0.02% 143

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

MB, Levis & Associates's MRNA Position: Q4 2025 in Review

MB, Levis & Associates sold out of Moderna (MRNA) in Q4 2025, closing a stake of 127 shares — an estimated $3.28K sold.

MB, Levis & Associates first reported a position in MRNA in Q4 2022 and held it in 12 quarters. The position peaked at $22.8K in Q4 2022. 674 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • MB, Levis & Associates reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • MB, Levis & Associates sold 127 Moderna shares in Q4 2025, an estimated $3.28K.
  • MB, Levis & Associates first reported a position in Moderna in Q4 2022 and held it in 12 quarters.
  • MB, Levis & Associates's Moderna position peaked at $22.8K in Q4 2022.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on MB, Levis & Associates's 13F filing for Q4 2025, filed 14 Jan 2026.